Transarterial Infusion Chemotherapy Using Cisplatin-Lipiodol Suspension With or Without Embolization for Unresectable Hepatocellular Carcinoma

Journal Article · Wed Jul 15 00:00:00 EDT 2009 · Cardiovascular and Interventional Radiology

DOI:https://doi.org/10.1007/S00270-009-9570-2· OSTI ID:21428495

Kawaoka, Tomokazu; Aikata, Hiroshi; Takaki, Shintaro; Katamura, Yoshio; Hiramatsu, Akira; Waki, Koji; Takahashi, Shoichi ^[1]; Hieda, Masashi; Toyota, Naoyuki; Ito, Katsuhide ^[2]; Chayama, Kazuaki ^[1]

---

1. Hiroshima University, Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Applied Biomedicine, Graduate School of Biomedical Science (Japan)
2. Hiroshima University, Department of Radiology, Division of Medical Intelligence and Informatics, Programs for Applied Biomedicine, Graduate School of Biomedical Science (Japan)

We evaluate the long-term prognosis and prognostic factors in patients treated with transarterial infusion chemotherapy using cisplatin-lipiodol (CDDP/LPD) suspension with or without embolization for unresectable hepatocellular carcinoma (HCC). Study subjects were 107 patients with HCC treated with repeated transarterial infusion chemotherapy alone using CDDP/LPD (adjusted as CDDP 10mg/LPD 1ml). The median number of transarterial infusion procedures was two (range, one to nine), the mean dose of CDDP per transarterial infusion chemotherapy session was 30 mg (range, 5.0-67.5 mg), and the median total dose of transarterial infusion chemotherapy per patient was 60 mg (range, 10-390 mg). Survival rates were 86% at 1 year, 40% at 3 years, 20% at 5 years, and 16% at 7 years. For patients with >90% LPD accumulation after the first transarterial infusion chemotherapy, rates were 98% at 1 year, 60% at 3 years, and 22% at 5 years. Multivariate analysis identified >90% LPD accumulation after the first transarterial infusion chemotherapy (p = 0.001), absence of portal vein tumor thrombosis (PVTT; p < 0.001), and Child-Pugh class A (p = 0.012) as independent determinants of survival. Anaphylactic shock was observed in two patients, at the fifth transarterial infusion chemotherapy session in one and the ninth in the other. In conclusion, transarterial infusion chemotherapy with CDDP/LPD appears to be a useful treatment option for patients with unresectable HCC without PVTT and in Child-Pugh class A. LPD accumulation after the first transarterial infusion chemotherapy is an important prognostic factor. Careful consideration should be given to the possibility of anaphylactic shock upon repeat infusion with CDDP/LPD.

• OSTI ID: 21428495
• Journal Information: Cardiovascular and Interventional Radiology, Vol. 32, Issue 4; Other Information: DOI: 10.1007/s00270-009-9570-2; Copyright (c) 2009 Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); ISSN 0174-1551
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
CHEMOTHERAPY
HEPATOMAS
INFUSION
LIPIODOL
MULTIVARIATE ANALYSIS
PLATINUM COMPLEXES
THROMBOSIS
VEINS
BLOOD VESSELS
BODY
CARCINOMAS
CARDIOVASCULAR DISEASES
CARDIOVASCULAR SYSTEM
COMPLEXES
CONTRAST MEDIA
DISEASES
INTAKE
MATHEMATICS
MEDICINE
NEOPLASMS
OILS
ORGANIC COMPOUNDS
ORGANIC HALOGEN COMPOUNDS
ORGANIC IODINE COMPOUNDS
ORGANS
OTHER ORGANIC COMPOUNDS
STATISTICS
THERAPY
TRANSITION ELEMENT COMPLEXES
VASCULAR DISEASES